The Global Ulcerative Colitis Market has been evaluated as growing market and expected that the market will reach high growth figures in the coming future. Ulcerative colitis is a type of inflammatory bowel disease (IBD) that usually affects the lower section of body such as sigmoid colon and the rectum. Belly pain or cramps, diarrhea and bleeding from the rectum are some of the common symptoms of the diseases.
Ulcerative Colitis Market – Key Players
Key players profiled in the report are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V., Janssen Biotech, and Merck
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2354
Key Developments:
Companies are continuously developing new products to capture the market globally. Thus major players invest more in research and development activity, in order to lead the global market. In this regard, market players undertake various strategic approaches.
Johnson & Johnson Services Inc.
September 2016: Acclarent Inc., a subsidiary of Johnson & Johnson, received FDA approval for ACCLARENT AERA Eustachian Tube Balloon Dilation System. It is a first FDA-approved device to treat Eustachian Tube Dysfunction effectively.
March 2016: Ethicon, a medical device company of the Johnson & Johnson, acquired NeuWave Medical, Inc.
June 2015: Verb Surgical Company was created by the collaboration of Ethicon and Verily.
March 2015: Ethicon, a medical device company of the Johnson & Johnson, enter into a collaboration with Google, Inc.
Pfizer Inc.
Pfizer Inc. is a leading research-based bio pharmaceutical organization. Pfizer apply science and our worldwide assets to convey inventive treatments that develop and essentially enhance lives. Pfizer makes medicines and vaccines that help individuals when they are sick and keep them from becoming sick in any case, and additionally a portion of some of the world’s best-known consumer healthcare brands.
August 2016: FDA approves Pfizer’s TROXYCA ER extended-release capsules CII for pain management. This drug is used for abuse-deterrent properties for the management of pain and will help Pfizer to improve their goodwill and sales with this new product
July 2016: Bind Therapeutics entered into an asset purchase agreement with Pfizer Inc. Bind Therapeutics Inc. entered into an asset purchase agreement with Pfizer, Inc. On July 26, 2016, company amended the stalking horse agreement. The acquisition is expected to close on or about August 1, 2016.
July 2016: Pfizer and Western Oncolytics announce immuno-oncology research collaboration. This collaboration has the aim to investigate novel oncolytic virus technology. Under terms of agreement, Pfizer and Western Oncolytics will collaborate on preclinical, clinical development of WO-12 through Phase I trials. Financial terms of agreement are not disclosed
June 2016: Pfizer completed the acquisition of Anacor Pharmaceuticals. This acquisition has a motive for Pfizer, so that the company can accelerate their shared commitment to help patients with inflammatory disease, an area of high unmet medical need
Merck:
January 2017: Merck Acquired BioControl to Strengthen Position in Food Safety Testing
August 2012: Merck Acquired Cell Culture Media Specialist Biochrom AG
Allergan
November 2017- Allergan plc company announced its data will be presented at the annual American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana, U.S. Allergan has a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company is an industry leader in Open Science, a model of research and development, which defines company’s approach to identifying and developing ideas and innovation for better patient care.
August 2016- Allergan acquired eye care company ForSight VISION5 which added peri-ocular ring technology to Company’s leading portfolio of innovative eye health products. Allergan has been a leader in the development and introduction of novel treatments for underserved eye conditions, including glaucoma, chronic dry eye disease and other ocular conditions. According to company reports, this acquisition of this ring technology that has profoundly change the way patients receive treatment. The ring is a preservative-free, non-invasive peri-ocular product that rests on the surface of the eye. It is inserted by an Ophthalmologist or Optometrist, and releases medication (bimatoprost) over multiple months to lower elevated IOP in glaucoma and ocular hypertensive patients.
Browse Complete 85 Pages Premium Research Report Enabled with Tables and Figures @https://www.marketresearchfuture.com/reports/ulcerative-colitis-market-2354
Ulcerative Colitis Market – Segmentation
Global Ulcerative Colitis Market is segmented on the basis of types and medication. Based on types, the market is segmented as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Ulcerative proctitis is expected to command the largest market share during the forecast period. Further on the basis of medication the market is classified into 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics. Biologics are expected to command the largest market. Steroids drugs are expected to grow at the highest CAGR during the forecast period.
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
List of Tables
Table 1 Global Ulcerative Colitis Market, By Type, 2013-2022 (USD Million)
Table 2 Global Ulcerative Colitis Market, By Medication, 2013-2022 (USD Million)
Table 3 Global Ulcerative Colitis Market by Region 2013-2022 (USD Million)
List of Figures
Figure 1 Research Process
Figure 2 Porters Five Forces Model
Figure 3 Global Ulcerative Colitis Market, By Type
Continued….
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/2354
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com